WELGLYCA
Live / Applied — Second extension granted (statement of use) (as of 06 Nov 2025)
What this means for you
Not registered yet, but its 23 Feb 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98418479
- Mark type
- Stylized text
- Filed
- 23 Feb 2024
- Published for opposition
- 29 Oct 2024
- Attorney of record
- Jessica L. Rothstein
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals for use in the treatment of oncological, cardiological, dermatological, neurological, genetic, orthopedic and metabolic diseases and disorders.
Owner
- Bridgebio Pharma, Inc., Palo Alto, CA, US
- Bridgebio Pharma, Inc., Palo Alto, CA, US
Prosecution history
- 07 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Nov 2025 — SOU EXTENSION 2 GRANTED
- 06 Nov 2025 — SOU EXTENSION 2 FILED
- 06 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 20 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 May 2025 — SOU EXTENSION 1 GRANTED
- 20 May 2025 — SOU EXTENSION 1 FILED
- 19 May 2025 — SOU TEAS EXTENSION RECEIVED
- 10 Dec 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 29 Oct 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 29 Oct 2024 — PUBLISHED FOR OPPOSITION
- 09 Oct 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 20 Sept 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 12 Sept 2024 — ASSIGNED TO EXAMINER
- 23 Feb 2024 — NEW APPLICATION ENTERED